Pricing Log in Create free account

Caris Life Sciences,�Inc. (CAI) vs Krystal Biotech, Inc. (KRYS)

Caris Life Sciences,�Inc. and Krystal Biotech, Inc. are both Biotechnology companies. Krystal Biotech, Inc. is the larger, with a market value of $8.9B against $7.4B — 1.2× the size. Krystal Biotech, Inc. trades at the lower P/E: 39.2× against 77.7×. Caris Life Sciences,�Inc. grew revenue faster over the last twelve months: 68.8% against 26.0%. Krystal Biotech, Inc. has the higher net margin (47.9% vs 9.16%) and the higher return on invested capital (27.2% vs 22.2%). Across the 19 metrics below, Krystal Biotech, Inc. leads on 15 and Caris Life Sciences,�Inc. on 4.

Valuation

Metric CAI KRYS Biotechnology median
P/E 77.71 39.21 10.26
P/S 7.15 18.92 9.18
P/B 12.66 6.20 2.05
Price to free cash flow 190.71 28.68 24.81
EV/EBITDA 39.40 34.07 0.65
EV/Sales 6.77 16.98 8.98
Earnings yield 1.29% 2.55% (34.89%)
Free cash flow yield 0.52% 3.49% (24.52%)

Profitability

Metric CAI KRYS Biotechnology median
Gross margin 0.00% 94.27% 65.16%
Operating margin 13.35% 48.41% 0.00%
Net margin 9.16% 47.91% 0.00%
Free cash flow margin 8.00% 65.97% 0.00%
Return on equity 0.00% 17.50% (50.12%)
Return on assets 8.58% 15.93% (45.60%)
Return on invested capital 22.24% 27.15% 0.00%

Growth

Metric CAI KRYS Biotechnology median
Revenue growth (TTM) 68.84% 25.96% 6.26%
EPS growth (last fiscal year) 69.79% 128.00% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric CAI KRYS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.71 7.89 4.89
Net debt to EBITDA (5.23) (4.93) 1.01

Dividend

Metric CAI KRYS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CAI KRYS Biotechnology median
Market cap 7.36b 8.90b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack